AXL and breast cancer: (4) MGCD265, which is a multi-targeted TKIs targeting MET, AXL, and PDGFR, completely inhibited the growth in only tumors with high MET gene copy gains, and combination of MGCD265 and erlotinib effectively inhibited the tumor growth in most of triple breast cancer cells and tumors49.